Self-Assessment Post-Test

SELF-ASSESSMENT POST-TEST There are no fees for participating and receiving CME credit for this activity. During the period May 2005 through May 31, 2006, participants must 1) read the learning objectives and faculty disclosures; 2) study the educational activity; 3) complete the post-test by recording the best answer to each question in the answer key on the evaluation form; 4) complete the evaluation form; and 5) mail or fax the evaluation form with answer key to the Postgraduate Institute for Medicine. A statement of credit will be issued only upon receipt of a completed activity evaluation form and a completed post-test with a score of 70% or better. Your statement of credit will be mailed to you within four weeks. Optimizing the Role of Hormonal Therapy in the Management of Prostate Cancer 1. 2. 3. 4. 5. 6. Complications of treatment with GnRH agonists include a. hot flushes. b. injection site reactions. c. testosterone flare. d. all of the above The correct definition of flare is a. extreme flushing, wherein the patient suffers severe discomfort. b. an increase in testosterone levels in response to initial treatment with a GNRH agonist. Side effects of flare in men with significant metastatic disease can include a. spinal cord compression. b. acute exacerbation of bone pain. c. a and b In the meta-analysis discussed by Dr. Lepor, which of the following are true in regard to survival? a. Orchiectomy is better than antiandrogen therapy alone. b. Diethylstilbestrol and the GnRH agonists are comparable to orchiectomy. c. Survival rates are lower for treatment with nonsteroidal antiandrogens. d. Among the GnRH agonists, none showed a statistical difference in survival. e. all of the above Dr. Chodak, in critiquing the meta-analysis of the effects of maximum androgen blockade (MAB), drew which of the following conclusions? a. For survival over 34 months, MAB was required. b. These meta-analysis results can be reliably interpreted as valid. c. A proportion of patients will have a substantial survival advantage through MAB. d. MAB should be continued for more than 120 days or until the onset of PSA progression. e. a, c, and d According to Dr. Gomella, the multi-modality treatment approach appears to benefit high-risk patients more than low-risk patients. a. true b. false 7. 8. 9. 10. 11. 12. 13. 14. In the D’Amico stratification scheme, newly diagnosed men are considered at intermediate risk of death from prostate cancer when a. PSA is
20 ng/mL, or Gleason Scale score is  8, and the 1992 AJCC classification is  T2C. b. PSA is 10–20 ng/mL, or Gleason Scale score is 7, and the 1992 AJCC classification is  T2B. c. PSA is  10 ng/mL, Gleason Scale score is  6, and the 1992 AJCC classification is T1C, 2A. d. PSA is  4 ng/mL, Gleason Scale score is  4, and the 1992 AJCC classification is  T2B According to Dr. Gomella, the use of standard monotherapy is an option for patients with high risk cancer of the prostate. a. true b. false Hot flushes occur in 50%-80% of men who are treated with androgen deprivation. a. true b. false Treatments for hot flushes can include a. acupuncture. b. soy products and vitamin E. c. estrogen. d. selective serotonin-reuptake in e. all of the above hibitor antidepressants. More than 80% of men with advanced prostate cancer have anemia. a. true b. false Methods for prevention of fractures include a. calcium supplementation, 1200 mg/day. b. treatment with a bisphosphonate. c. vitamin D, 600-800 IU/day. d. all of the above Besides the prostate gland, source(s) of serum PSA include a. breast cancer. b. gynecomastia. c. thyroid tumors. d. There is no appreciable source of PSA outside the prostate. The current consensus is that biological failure of treatment (PSA recurrence) is initially identified at a. PSA  0.2 ng/mL b. PSA  0.3 ng/mL c. PSA  0.5 ng/mL d. PSA  0.6 ng/mL EVALUATION FORM Optimizing the Role of Hormonal Therapy in the Management of Prostate Cancer Supplement Project ID: 2739-ES 13 Postgraduate Institute for Medicine (PIM) respects and appreciates your opinions. To assist us in evaluating the effectiveness of this activity and to make recommendations for future educational offerings, please take a few minutes to complete this evaluation form. You must complete this evaluation form to receive acknowledgement of participation for this activity. Please answer the following questions by circling the appropriate rating: 5 = Outstanding 4 = Good 3 = Satisfactory 2 = Fair 1 = Poor EXTENT TO WHICH PROGRAM ACTIVITIES MET THE IDENTIFIED OBJECTIVES Upon completion of this activity, participants should be better able to: • Compare single-agent androgen suppression for advanced prostate cancer. • Discuss androgen blockade. • Identify the needs of the high-risk prostate cancer patient. • Review the effective management of biochemical recurrence in patients with prostate cancer. • Review adverse events associated with hormonal therapy for prostate cancer. • Discuss reimbursement issues with hormonal therapies for prostate cancer. VOL. 7 SUPPL. 5 2005 5 5 5 5 5 5 4 4 4 4 4 4 3 3 3 3 3 3 REVIEWS IN UROLOGY 2 2 2 2 2 2 1 1 1 1 1 1 S49 OVERALL EFFECTIVENESS OF THE ACTIVITY • • • • Was timely and will influence how I practice Will assist me in improving patient care Fulfilled my educational needs Avoided commercial bias or influence 5 5 5 5 4 4 4 4 3 3 3 3 2 2 2 2 IMPACT OF THE ACTIVITY The information presented: (check all that apply) ❒ Reinforced my current practice/treatment habits ❒ Provided new ideas or information I expect to use ❒ Will improve my practice/patient outcomes ❒ Enhanced my current knowledge base Will the information presented cause you to make any changes in your practice? ❒ Yes ❒ No If yes, please describe any change(s) you plan to make in your practice as a result of this activity: How committed are you to making these changes? 5 (Very committed) 4 3 2 1 (Not at all committed) FUTURE ACTIVITIES Do you feel future activities on this subject matter are necessary and/or important to your practice? ❒ Yes ❒ No Please list any other topics that would be of interest to you for future educational activities: FOLLOW-UP As part of our ongoing continuous quality-improvement effort, we conduct post-activity follow-up surveys to assess the impact of our educational interventions on professional practice. Please indicate your willingness to participate in such a survey: ❒ Yes, I would be interested in participating in a follow-up survey ❒ No, I’m not interested in participating in a follow-up survey Additional comments about this activity: POST-TEST ANSWER KEY 1___ 2___ 3___ 4___ 5___ 6___ 7___ 8___ 9___ 10___ 11___ 12___ 13___ 14___ Request for Credit Name Degree Organization Specialty Address City, State, Zip Telephone Fax E-Mail I certify my actual time spent to complete this educational activity to be: ❒ I participated in the entire activity and claim 2.0 credits. ❒ I participated in only part of the activity and claim _____ credits. Signature S50 VOL. 7 SUPPL. 5 2005 If you wish to receive acknowledgement of participation for this activity, please complete the post-test by selecting the best answer to each question, complete this evaluation verification of participation, and FAX to: 303-790-4876 Date Completed REVIEWS IN UROLOGY 1 1 1 1